Pimecrolimus: Absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro

Drug Metabolism and Disposition

Volumn 34, Issue 5, 2006, Pages 765-774

  Zollinger, Markus ^a   Waldmeier, Felix ^a   Hartmann, Stefan ^a   Zenke, Gerhard ^a   Zimmerlin, Alfred G ^a   Glaenzel, Ulrike ^a   Baldeck, Jean Pierre ^a   Schweitzer, Alain ^a   Berthier, Stephane ^a   Moenius, Thomas ^a   Grassberger, Maximilian A ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Novartis Institutes for BioMedical Research ^*

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; PIMECROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; AEROBIC METABOLISM; ANIMAL CELL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CELLULAR DISTRIBUTION; DEMETHYLATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; FECES ANALYSIS; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFORMATION; ISOTOPE LABELING; LIVER MICROSOME; MALE; METABOLITE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; T LYMPHOCYTE ACTIVATION; TIME; TISSUE DISTRIBUTION; TISSUE LEVEL; VOLUNTEER;

ADULT; AREA UNDER CURVE; BIOTRANSFORMATION; BLOOD CELLS; CYTOCHROME P-450 ENZYME SYSTEM; FECES; GENES, REPORTER; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; INTESTINAL ABSORPTION; ISOENZYMES; KINETICS; MALE; MICROSOMES, LIVER; TACROLIMUS; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 33645806107     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.007732     Document Type: Article

References (24)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Eichenfield LF and Beck L (2003) Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol 111:1153-1168.
3. Gottlieb AB, Griffiths CEM, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne J-P, Todd G, Cherill R, Marks I, et al. (2005) Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br J Dermatol 152:1219-1227.
4. Graham-Brown RAC and Grassberger M (2003) Pimecrolimus: a review of pre-clinical and clinical data. Int J Clin Pract 57:319-327.
5. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, Schuler W, Schulz M, Werner F-J, Winiski A, et al. (1999) A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141:264-273.
6. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
7. Hughes P, Musser J, Conklin M, and Russo R (1992) The isolation, synthesis and characterization of an isomeric form of rapamycin. Tetrahedron Lett 33:4739-4742.
8. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, and Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36:89-96.
9. Moenius T, Baumann K, Bulusu M, Schweitzer A, and Voges R (2001) Labeling of pharmacologically active macrocycles, in Synthesis and Applications of Isotopically Labeled Compounds (Pleiss U and Voges R eds) vol 7, pp 424-429, John Wiley & Sons, Chichester.
10. Namiki Y, Kihara N, Koda S, Hane K, and Yasuda T (1993) Tautomeric phenomenon of a novel potent immunosuppressant (FK506) in solution: I. Isolation and structure determination of tautomeric compounds. J Antibiot (Tokyo) 46:1149-1155.
11. Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C, and Ortonne JP (2000) SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 42:349-350.
12. Rappersberger K, Komar M, Ebelin M-E, Scott G, Burtin P, Greig G, Kehren J, Chibout S-D, Cordier A, Holter W, et al. (2002) Pimecrolimus identifies a common genomic antiinflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Investig Dermatol 119:876-887.
13. Richmond CR, Langham WH, and Trujillo TT (1962) Comparative metabolism of tritiated water by mammals. J Cell Comp Physiol 59:45-53.
14. Rigopoulos D, Ioannides D, Kalogeromitros D, Gregoriou S, and Katsambas A (2004) Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrheic dermatitis. A randomized open-label clinical trial. Br J Dermatol 151:1071-1075.
15. Scheline RR (1973) Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 25:451-523.
16. Scott G, Osborne SA, Greig G, Hartmann S, Ebelin M-E, Burtin P, Rappersberger K, Komar and Wolff K (2003) Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. Clin Pharmacokinet 42:1305-1314.
17. Smith DA and Jones BC (1992) Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44:2089-2098.
18. Smith RV (1978) Metabolism of drugs and other foreign compounds by intestinal microorganisms. World Rev Nutr Diet 29:60-76.
19. Streit F, Christians U, Schiebel H-M, Meyer A, and Sewing K-F (1996) Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos 24:1272-1278.
20. Vidal C, Kirchner GI, and Sewing K-F (1998) Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD. J Am Soc Mass Spectrom 9:1267-1274.
21. Wellington K and Noble N (2004) Pimecrolimus: a review of its use in atopic dermatitis. Am J Clin Dermatol 5:479-495.
22. Wolff K, Caro I, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M, Shear N, Silny W, Korman N, et al. (2003) Treatment with oral pimecrolimus improves atopic eczema with a clear dose-response effect (conference abstract). J Eur Acad Dermatol Venereol 17 (Suppl 3):182-183 (P2-38).
23. Zenke G, Strittmatter U, Fuchs S, Quesniaux VFJ, Brinkmann V, Schuler W, Zurini M, Enz A, Billich A, Sanglier J-J, et al. (2001) Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action. J Immunol 166:7165-7171.
24. Zollinger M, Glaenzel U, and Baldeck J-P (2002) Species comparison of the metabolism of pimecrolimus: a complex problem solved by LC-MS (conference abstract). Proceedings of the 50th ASMS Conference on Mass Spectrometry and Allied Topics, Orlando, Florida, June 2-6, 2002.